Verenium Reports Financial Results for the Third Quarter and Nine Months Ended Septembe...( - Continued progress in both core ...),Health

- Continued progress in both core business segments supports growth -

CAMBRIDGE, Mass., Nov. 6 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a leading developer of technologies for cellulosic ethanol production and a pioneer in the development of high-performance specialty enzymes, today reported financial results for the third quarter and nine months ended September 30, 2007.

"We are very pleased with the progress the Company has made in both our biofuels and enzyme business areas over the last quarter and in the months since our recent merger," said Carlos A. Riva, Verenium's President and Chief Executive Officer. "We are at the forefront of a significant global market opportunity with the development of next-generation biofuels, and believe Verenium is poised to make an important impact as we continue to advance our key programs and technologies towards making cellulosic ethanol a commercial reality."

Financial Results

Selected Financial Information

(unaudited, in thousands, except per share amounts)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Revenues:

Product:

Phyzyme(TM) phytase $3,591 $2,905 $11,047 $6,578

All other products 2,740 1,785 6,680 3,988

Total product 6,331 4,690 17,727 10,566

Collaborative 4,075 9,200 13,202 22,149

Grant 455 422 2,374 1,
'/>"/>